Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 235,258 shares, an increase of 2,710.1% from the August 31st total of 8,372 shares. Approximately 4.2% of the shares of the company are sold short. Based on an average trading volume of 748,437 shares, the days-to-cover ratio is presently 0.3 days.
Redhill Biopharma Trading Down 4.2%
RDHL stock traded down $0.02 during trading on Thursday, reaching $0.52. The stock had a trading volume of 88,639 shares, compared to its average volume of 855,862. The firm has a market cap of $3.16 million, a PE ratio of 0.00 and a beta of 4.96. The stock’s 50 day moving average is $0.65 and its two-hundred day moving average is $0.80. Redhill Biopharma has a 52 week low of $0.52 and a 52 week high of $2.79.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Redhill Biopharma in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Institutional Trading of Redhill Biopharma
A hedge fund recently raised its position in Redhill Biopharma stock. Gagnon Securities LLC raised its holdings in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 383.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,102 shares of the biotechnology company’s stock after buying an additional 68,280 shares during the period. Gagnon Securities LLC owned about 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 7.20% of the company’s stock.
About Redhill Biopharma
RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities.
RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S.
Further Reading
- Five stocks we like better than Redhill Biopharma
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
